Fettleibigkeit
NeuClinical trial of a new compound that is being developed for the treatment of obesity and a fatty, inflamed liver.
- Rauchen
- Nicht-raucher
- Geschlecht
- Mann
- Alter
- 18-55 jaar
Clinical trial of a new compound that is being developed for the treatment of heart failure.
Note: You cannot participate in the trial if you have participated in another clinical trial in the 30 days prior to the screening in this clinical trial (counting from the last dosing). For some study compounds this can be 90 days. This will be discussed during your telephone screening.
To determine if you are suitable to participate in this trial, you will undergo a medical screening. Depending on availability, this can be performed in Groningen or in Utrecht.
Group 1 and 2
The trial consists of 1 period during which you will stay in the research facility in Groningen (location van Swietenlaan 6) for 7 days (6 nights). After this period there will be 3 short visits. The follow-up will take place during the last short visit. If the results of Group 1 show that more short visits are needed than planned, then Group 2 may have 8 short visits instead of 3 short visits. You will be informed about this at the start of the study.
Group 3
The trial consists of 1 period during which you will stay in the research facility in Groningen (location van Swietenlaan 6) for 7 days (6 nights). After this period there will be 5 short visits. The follow-up will take place during the last short visit. If the results of Group 1 and 2 show that more short visits are needed than planned, then Group 3 may have 8 short visits instead of 5 short visits. You will be informed about this at the start of the study.
Group 4, 5 and 6
The trial consists of 1 period during which you will stay in the research facility in Groningen (location van Swietenlaan 6) for 7 days (6 nights). After this period there will be 8 short visits. The follow-up will take place during the last short visit.
Note: You must be available for all dates to be able to participate in this clinical trial. The current dates of the clinical trial will be published on our website.
You will receive a gross compensation of €2321 for participation in group 1. You will receive a gross compensation of €2387 for participation in group 2. For group 2 you will receive a gross compensation of €3683 if there are 8 short visits needed. You will receive a gross compensation of €2859 for participation in group 3. For group 3 you will receive a gross compensation of €3683 if there are 8 short visits needed. You will receive a gross compensation of €3683 for participation in group 4, 5 or 6. Travel expenses will be reimbursed based on the distance traveled (€ 0.21 net per kilometer) with a minimum of € 13 and a maximum of € 176.40 (840 kilometers) per round trip, regardless of the mode of transportation.